Create a free research account to view current pricing and place an order.
How does PT-141 work in research models?
PT-141/bremelanotide is a melanocortin receptor agonist, primarily acting through MC3R/MC4R pathways associated with sexual arousal signaling and central nervous system melanocortin activity.
What is the half-life of PT-141?
Half-life: Approx. 2.7 hours for approved bremelanotide formulation.
FDA labeling for bremelanotide describes a terminal half-life of about 2.7 hours, with peak concentration around 1 hour in clinical autoinjector formulations.
Research dosing reference
1.25-1.75 mg PRN research reference; avoid frequent repeated exposure.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 1.25 mg | 25 units |
| 1.75 mg | 35 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
How is PT-141 reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Typically timed several hours before intended effect window; avoid first exposure in high-stakes situations.
Beginner escalation
Start conservatively due to nausea, flushing, blood pressure, and CNS-response variability.
Side-effect mitigation
Monitor nausea, flushing, headache, blood pressure changes, hyperpigmentation risk, and prolonged arousal response.
Stack compatibility
Avoid stacking with other melanocortin agents or BP-active compounds without review.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Use as intermittent/situational exposure, not continuous daily cycling. Reassess frequency, blood pressure response, nausea, and melanocortin-related effects before repeat use.
Frequently asked questions
What is PT-141 and how is it studied?
PT-141/bremelanotide is a melanocortin receptor agonist, primarily acting through MC3R/MC4R pathways associated with sexual arousal signaling and central nervous system melanocortin activity. PT-141 is catalogued in the Hormonal / Miscellaneous group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of PT-141?
Reference half-life for PT-141: approx. 2.7 hours for approved bremelanotide formulation. FDA labeling for bremelanotide describes a terminal half-life of about 2. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal.
How is PT-141 stored?
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is PT-141 reconstituted for laboratory work?
The reference reconstitution for the 10 mg vial is 2 mL BAC Water, which gives a concentration of about 5 mg/mL. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is PT-141 FDA approved?
No. The research-grade PT-141 described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
PT-141 product overview · PT-141 cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration